Who We Are
Reneo Pharmaceuticals is a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases.
Reneo is initially developing mavodelpar (REN001) in two rare genetic diseases that typically present with myopathy: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
We completed a Phase 1b clinical trial in patients with PMM and are currently enrolling patients in a global Phase 2b clinical trial (STRIDE Study). In addition, we conducted two exploratory Phase 1b clinical trials of mavodelpar in patients with LC-FAOD and McArdle disease, respectively.
Meet the Reneo Executive Team!
President & Chief Executive Officer
Chief Medical Officer
Chief Development Officer
Chief Operating Officer
Chief Business Officer
Senior Vice President, Global Development
Executive Chairman
Mike Grey is executive chairman and a founder of Reneo Pharmaceuticals. He also serves as executive chairman of Plexium, Inc. and Spruce Biosciences, chairman of Mirum Pharmaceuticals, and is venture partner at Pappas Ventures. Previously, he founded and was president and CEO at Lumena Pharmaceuticals, a company developing treatments for pediatric and adult orphan diseases, until its acquisition by Shire.
Mike has more than 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies. Past positions include executive chair of Amplyx Pharmaceuticals (acquired by Pfizer), Ziarco Pharma (acquired by Novartis), president and CEO of Auspex Pharmaceuticals, president and CEO of SGX Pharmaceuticals (acquired by Eli Lilly), president and CEO of Trega Biosciences (acquired by Lion Bioscience) and president of BioChem Therapeutic. For approximately 20 years, Mike served in various roles with Glaxo and Glaxo Holdings plc, culminating in his position as vice president, corporate development and head of international licensing.
Mike also serves on the board of directors of Horizon Pharma and Mirati Therapeutics.
Executive Chairman
Eric Dube, Ph.D., is the president, chief executive officer and a director of Travere Therapeutics, a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare disease. Prior to joining Travere, Dr. Dube served as president and head of North America at ViiV Healthcare and spent more than 18 years working in roles of increasing leadership at GlaxoSmithKline across the United States, Europe and Japan. He currently serves on the board of trustees for AIDS United and the board of directors for the Biotechnology Innovation Organization (BIO), Biocom California and Reneo Pharmaceuticals.
Dr. Dube has been recognized by PharmaVOICE magazine as one of the “100 Most Inspiring People” in the life sciences industry, and the Financial Times as one of the “OUTstanding 100 LGBT+ Executives. Earlier in his career, Fortune magazine named him a “40 Under 40: Ones to Watch”.
Dr. Dube graduated from Santa Clara University with a B.S. in biopsychology and earned an M.A. and Ph.D. in psychology from Cornell University.
Greg is the president and chief executive officer of Reneo Pharmaceuticals and serves as a member of the company’s board of directors. Greg brings to Reneo more than 25 years of biopharmaceutical industry experience in executive management, corporate and business development, operations, sales and marketing, and clinical development. He has been closely involved with several novel development programs resulting in multiple product approvals and successful commercial launches in the U.S. and Europe.
Prior to joining Reneo, Greg was chief executive officer and a member of the board of directors of Novus Therapeutics (Nasdaq: NVUS), a clinical-stage pharmaceutical company he took public in 2017 and led through the transformational acquisition of Anelixis Therapeutics in 2020. Prior to Novus, Greg was chief business officer of publicly traded Avanir Pharmaceuticals (AVNR), a commercial-stage pharmaceutical company, where he led corporate and business development as well as corporate operations through the $3.5 billion acquisition of the company by Otsuka Pharmaceuticals in 2015. From 1995 to 2006, Greg held multiple leadership roles at Intermune (acquired by Roche), Amgen, and Eli Lilly and Company.
Greg received his B.S. in biology from Purdue University and studied biochemistry and molecular biology at Indiana University School of Medicine.
Paul W. Hoelscher served as executive vice president, chief financial officer of Horizon Therapeutics plc, a biotech company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases, from 2014 until his retirement in 2022.
Prior to joining Horizon in 2014, Mr. Hoelscher held financial executive positions for two years at OfficeMax, Inc., a business services company, held financial leadership roles of increasing responsibility over nineteen years at Alberto Culver Company, a beauty care company, and worked in the audit practice of KPMG LLP for seven years.
Mr. Hoelscher received his B.S. in accountancy from the University of Illinois at Urbana-Champaign and is a certified public accountant. Paul served on the board of trustees of the Illinois Region of The Leukemia & Lymphoma Society from 2007 to 2022, including two terms as board chair, and serves on the Chicago Regional Advisory Committee for The Ireland Funds.
Ed Mathers joined NEA as a partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals (NASDAQ:RARX), Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic,(NASDAQ:SYBX), Lumos Pharma, Senti Biosciences, Inozyme, Akouos, Trevi Therapeutics and ObsEva (NASDAQ:OBSV).
Previously, he was a board member of Lumena (sold to Shire), Ziarco (sold to Novartis), Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune and the Biotechnology Industry Organization (BIO).
Prior to joining NEA, Ed served as executive vice president, corporate development and venture, at MedImmune Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures. Before joining MedImmune in 2002, he was vice president of marketing, corporate licensing and acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor’s degree in chemistry from North Carolina State University.
Bali has 15 years professional experience in healthcare across a range of functions including venture investing, R&D, clinical practice and teaching. He works with the team in the London, Boston and Menlo Park offices to source and evaluate new investment opportunities and support existing venture investments through to exit. He represents Abingworth on the boards of Anjarium, Exicure Inc., Gynesonics, Glycomine, NuCana, Reneo, Spruce Biosciences and Wugen. He is also an executive officer on the joint steering committee of CymaBay.
Prior to joining Abingworth, Bali was a senior partner at MVM Partners LLP in London where he completed investments in and served on the boards of several companies, both public and private. Two of these were Wilson Therapeutics and Valneva, both also Abingworth portfolio companies. In 2018, Bali was named among Financial News’ Rising Stars in Private Equity, which celebrated 25 men and women under the age of 40 standing out in the European private equity industry. Before MVM, Bali was a member of Bain Capital’s healthcare deal team.
Bali obtained a degree in clinical medicine from the University of Oxford and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals in Oxford and Cambridge, respectively. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer-reviewed papers. He was also a Bye-Fellow in Medical Sciences at Downing College, Cambridge where he taught pathology, surgery and medicine.
Niall O’Donnell, Ph.D., co-founder of Reneo Pharmaceuticals and managing director of RiverVest Venture Partners. Niall previously served as interim chief medical officer at Lumena Pharmaceuticals, where he was central to the development and execution of the company’s clinical strategy prior to its acquisition by Shire in 2014. He also helped co-found Excaliard Pharmaceuticals and developed the company’s clinical strategy. Excaliard was acquired by Pfizer in 2011.
Prior to joining RiverVest in 2006, Niall worked at Johnson & Johnson Pharmaceutical Research and Development in San Diego. He earned his Ph.D. in biochemistry from the University of Dundee, Scotland, and an M.A. in biochemistry from Pembroke College, Oxford. He also received an M.B.A. from the Rady School of Management of the University of California, San Diego. He is a board member of Lyric Pharmaceuticals, Spruce Biosciences, Mirum Pharmaceuticals and Avalyn Pharmaceuticals.
Most recently, Ms. Seltzer served as a Partner at Aisling. While at Aisling, her board service included Agile Therapeutics, Aimmune Therapeutics (acquired by Nestle Health Sciences), AVROBIO, Durata Therapeutics (acquired by Actavis), Miramar Labs (acquired by Sientra), Prolacta Bioscience, Promentis Pharmaceuticals, Spruce Biosciences, Wugen and ZELTIQ Aesthetics (acquired by Allergan). She also acted as the Aisling representative for its investment in PreCision Dermatology (acquired by Valeant). Prior to Aisling, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving at U.S. Schering-Plough as Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.
Ms. Seltzer serves on the Life Science Council for Springboard Enterprises and the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale. Ms. Seltzer received her MBA from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar, and her M.S. and B.S. in molecular biophysics and biochemistry from Yale University, awarded cum laude.
Ms. Seltzer currently serves as a board observer of Prolacta Bioscience and Spruce Biosciences. Her prior board service includes Agile Therapeutics, Aimmune Therapeutics (acquired by Nestle Health Sciences), AVROBIO, Durata Therapeutics (acquired by Actavis), Miramar Labs (acquired by Sientra), Promentis Pharmaceuticals and ZELTIQ Aesthetics (acquired by Allergan). She also acted as the Aisling representative for its investment in PreCision Dermatology (acquired by Valeant). Ms. Seltzer serves on the Life Science Council for Springboard Enterprises and the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale.
Ms. Seltzer received her MBA from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar, and her M.S. and B.S. in molecular biophysics and biochemistry from Yale University, awarded cum laude.
